3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 6 areas
0
News (30d)
Quiet
CG Pharmaceuticals, Inc. is a company with 3 orphan drug designations across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| acute myeloid leukemia | Ivaltinostat | Des.TrialAppr. |
| hepatocellular carcinoma | Ivaltinostat | Des.TrialAppr. |
| malignant pancreatic neoplasm | (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
43
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
43
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio